Dementia Rx May Lower Risk of Falls Among Parkinson's Patients

This article originally appeared here.
Share this content:
Dementia Rx May Lower Risk of Falls Among Parkinson's Patients
Dementia Rx May Lower Risk of Falls Among Parkinson's Patients

THURSDAY, Jan. 14, 2016 (HealthDay News) -- Rivastigmine shows potential in reducing the risk of falls among patients with Parkinson's disease, according to new research published online Jan. 12 in The Lancet Neurology.

The study included 130 people with Parkinson's disease who had fallen in the past year. Half took the medication rivastigmine, while the other half took a placebo.

After eight months, those who took rivastigmine were much steadier when walking and 45 percent less likely to fall than those who took the placebo, according to the researchers.

"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine; however, our study shows for the first time that it can also improve regularity of walking, speed, and balance," lead author Emily Henderson, M.B.Ch.B., from the University of Bristol in the United Kingdom, said in a Parkinson's UK news release. "This is a real breakthrough in reducing the risk of falls for people with Parkinson's."

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »